A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis.

Conditions:   Psoriatic Arthritis;   Ankylosing Spondylitis;   Non-Radiographic Axial Spondyloarthritis Interventions:   Drug: tildrakizumab 200 mg (two 1-mL injections of 100 mg/mL);   Drug: tildrakizumab 100 mg (one 1-mL injection of 100 mg/mL + 1 mL placebo) Sponsor:   Sun Pharma Global FZE Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials